NasdaqGM:SESN

Stock Analysis Report

Executive Summary

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer.

Snowflake

Fundamentals

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Sesen Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.4%

SESN

0.8%

US Biotechs

1.0%

US Market


1 Year Return

-34.7%

SESN

-8.3%

US Biotechs

6.7%

US Market

Return vs Industry: SESN underperformed the US Biotechs industry which returned -8.3% over the past year.

Return vs Market: SESN underperformed the US Market which returned 6.7% over the past year.


Share holder returns

SESNIndustryMarket
7 Day-7.4%0.8%1.0%
30 Day0%-3.9%-1.8%
90 Day-12.4%-3.5%-1.8%
1 Year-34.7%-34.7%-7.5%-8.3%9.1%6.7%
3 Year-44.6%-44.6%13.6%9.6%46.1%36.6%
5 Year-89.7%-89.7%3.3%-1.7%66.9%48.6%

Price Volatility Vs. Market

How volatile is Sesen Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sesen Bio undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: SESN ($1.13) is trading below our estimate of fair value ($21.81)

Significantly Undervalued: SESN is trading below fair value by more than 20%.


Price Based on Earnings

PE vs Industry: SESN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SESN is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate SESN's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: SESN is overvalued based on its PB Ratio (7.4x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Sesen Bio expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

32.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: SESN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SESN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SESN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SESN's revenue (71.5% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: SESN's revenue (71.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if SESN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sesen Bio performed over the past 5 years?

-7.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SESN is unprofitable, and losses have increased over the past 5 years at a rate of -7.3% per year.

Accelerating Growth: Unable to compare SESN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SESN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: SESN has a negative Return on Equity (-530.85%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SESN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SESN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Sesen Bio's financial position?


Financial Position Analysis

Short Term Liabilities: SESN's short term assets ($67.5M) exceeds its short term liabilities ($7.9M)

Long Term Liabilities: SESN's short term assets (67.5M) do not cover its long term liabilities (104.3M)


Debt to Equity History and Analysis

Debt Level: SESN is debt free.

Reducing Debt: SESN has no debt compared to 5 years ago when its debt to equity ratio was 9.6%.


Balance Sheet

Inventory Level: SESN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SESN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SESN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SESN has sufficient cash runway for 1.614274 years if free cash flow continues to reduce at historical rates of -45.1% each year.


Next Steps

Dividend

What is Sesen Bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate SESN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SESN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SESN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SESN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SESN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Sesen Bio's salary, the management and board of directors tenure and is there insider trading?

0.5yrs

Average management tenure


CEO

Thomas Cannell (57yo)

1.2yrs

Tenure

US$2,009,874

Compensation

Dr. Thomas R. Cannell, DVM, is President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June 8, 201 ...


CEO Compensation Analysis

Compensation vs. Market: Thomas has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.


Management Age and Tenure

0.5yrs

Average Tenure

57yo

Average Age

Experienced Management: SESN's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Age and Tenure

4.8yrs

Average Tenure

60.5yo

Average Age

Experienced Board: SESN's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Greg Verdine (60yo)

    Co-Founder

    • Tenure: 0yrs
  • Greg Adams (60yo)

    Chief Scientific Officer

    • Tenure: 0yrs
  • Glen MacDonald (68yo)

    Chief Technology Officer

    • Tenure: 0yrs
  • Chris Garcia

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Casey Weaver

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Kirstin Anderson (46yo)

    Corporate Controller & Principal Accounting Officer

    • Tenure: 0.2yrs
  • Thomas Cannell (57yo)

    President

    • Tenure: 1.2yrs
    • Compensation: US$2.01m
  • Dennis Kim (50yo)

    Chief Medical Officer

    • Tenure: 0.8yrs
    • Compensation: US$709.28k
  • Monica Forbes (43yo)

    Chief Financial Officer

    • Tenure: 0.2yrs
  • Erin Clark

    Vice President of Corporate Strategy & Investor Relations

    • Tenure: 0yrs

Board Members

  • Dan Lynch (61yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: US$130.30k
  • Wendy Dixon (64yo)

    Chairman

    • Tenure: 2.8yrs
    • Compensation: US$257.57k
  • Patricia D'Amore (67yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jane Pritchett Henderson (53yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: US$133.43k
  • Peter Campochiaro

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jay Duker (60yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$113.78k
  • Chris Garcia

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Reza Dana

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Casey Weaver

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Thomas Cannell (57yo)

    President

    • Tenure: 1.2yrs
    • Compensation: US$2.01m

Company Information

Sesen Bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sesen Bio, Inc.
  • Ticker: SESN
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$114.430m
  • Shares outstanding: 101.27m
  • Website: https://www.sesenbio.com

Number of Employees


Location

  • Sesen Bio, Inc.
  • 245 First Street
  • Suite 1800
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SESNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2014
PCBKDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company’s le ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 02:54
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)